1.
Latent classes in the adult Dutch population, based on four types of capital.
2.
3.
4.
5.
6.
7.
8.
9.
S3 Fig -
S5 Fig -
S6 Fig -
CBP per cumulative year for daratumumab and pembrolizumab per vial.
CBP per cumulative indication for daratumumab and pembrolizumab per vial.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Implementation of indication-based pricing (10 th scenario) for daratumumab and pembrolizumab.
Input parameters for the base-case analysis.